Nomegestrol acetate
Small moleculeexperimental
Nomegestrol acetate (NOMAC), sold under the brand names Lutenyl and Zoely among others, is a progestin medication which is used in birth control pills, menopausal hormone therapy, and for the treatment of gynecological disorders. It is available both alone and in combination with an estrogen. NOMAC is taken by mouth. A birth control implant for placement under the skin was also developed but ultimately was not marketed. — Wikipedia
Clinical trial activity
12 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
4
Phase 4
3
Earliest trial started Jun 1, 2005 (NCT00127075)
Timeline
Indications
Approved for
Mechanism of action
- Progesterone receptorAGONIST
PGR agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C- Mol. weight
- 370.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNomegestrol acetate ↗
- ChEMBLCHEMBL2105722 ↗
- ChEMBLCHEMBL1476022 ↗
Also known as
- 19-norpregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-
- lutenyl
- nomegestrol
- nomegestrol
- nomegestrol
- nomegestrol
- nomegestrol
- nomegestrol
- nomegestrol
- nomegestrol acetate
- nomegestrol acetate
- nomegestrol acetate
- nomegestrol acetate
- nomegestrol acetate
- nomegestrol acetate
- org-10486-0
- org-10486-0
- tx 066
- tx 066
- tx 066
- tx 066
- tx 066
- tx-066
- tx-066
- tx-066
- tx-066
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05264506 | Phase 3 | Feb 17, 2022 | IQVIA, Organon |
| NCT03749733 | Phase 1 | Oct 31, 2019 | Grunenthal |
| NCT03077555 | Phase 4 | Jan 21, 2017 | Mahidol University |
| NCT03531437 | Phase 4 | Mar 31, 2016 | Mahidol University |
| NCT01723579 | Phase 3 | Jul 1, 2013 | Merck |
| NCT01715025 | Phase 4 | Apr 1, 2013 | Merck, Sydney Centre for Reproductive Health Research |
| NCT01670656 | Phase 2 | Jan 1, 2013 | Merck |
| NCT01709318 | Phase 2 | Dec 1, 2012 | Merck |
| NCT01656434 | Phase 3 | Nov 1, 2012 | Merck |
| NCT01345786 | Phase 1 | Nov 1, 2009 | Merck |
| NCT00711607 | Phase 1 | May 1, 2007 | CRS Clinical Research Services Kiel GmbH, Merck |
| NCT00127075 | Phase 3 | Jun 1, 2005 | University of Lyon |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 7 | 6 | 4 | 2007 |
| Mahidol University | Academic/Hospital | 2 | 2 | 1 | 2016 |
| CRS Clinical Research Services Kiel GmbH | For profit | 1 | 0 | 1 | 2007 |
| Grunenthal | For profit | 1 | 1 | 1 | 2019 |
| IQVIA | For profit | 1 | 0 | 1 | 2022 |
| Organon | For profit | 1 | 1 | 1 | 2022 |
| Sydney Centre for Reproductive Health Research | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Lyon | Academic/Hospital | 1 | 1 | 1 | 2005 |
8 organizations
Page 1 / 1